Core One Labs (XCNQ:COOL) Change In Working Capital : C$-0.34 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Core One Labs Change In Working Capital?

Core One Labs's change in working capital for the quarter that ended in Dec. 2023 was C$0.00 Mil.

Core One Labs's change in working capital for the fiscal year that ended in Dec. 2021 was C$1.80 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Core One Labs Change In Working Capital Historical Data

The historical data trend for Core One Labs's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Change In Working Capital Chart

Core One Labs Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Working Capital

Get a 7-Day Free Trial

1.12

-0.26

1.42

1.98

1.80

Core One Labs Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-1.17	1.68	-0.34	-	-

Core One Labs Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.34 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Core One Labs Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Core One Labs's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Core One Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5

Website

https://www.core1labs.com

Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.

Executives

Geoffrey Balderson	Director, Senior Officer
Joel Shacker	Director, Senior Officer
Robert E.w. Hancock	Director
Brad Eckenweiler	10% Security Holder, Director, Senior Officer